Aitia
- Company typePrivate
- Founded2000
- HeadquartersSomerville, United States
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
Aitia firmographics
Firmographics- Name
- Aitia
- Legal name
- Aitia
- Website
- https://aitiabio.com
- Company type
- Private
- Founded year
- 2000
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
Aitia industry classification
Industry- Product category
- Drug Discovery Software
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Computer Systems Design and Related Services (54151)
- SIC
- Services-Computer Integrated Systems Design (7373), Services-Health Services (8000)
- akta.pro primary industry
- AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)
- akta.pro secondary industry
- AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE)
Keywords
Where Aitia is headquartered
LocationHeadquarters
- HQ city
- Somerville
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Aitia business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Infrastructure, Marketing or Sales, Operations
Revenue model
- Pharmaceutical Partnership Programs: Aitia partners with biopharma companies to discover, develop, and test novel therapeutics using their Gemini Digital Twins platform. Revenue is generated through strategic partnerships that fuel differentiated and novel partnered programs across multiple disease areas with high unmet medical need.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels3 records
Aitia product offering
Product offeringCore offering
Aitia develops and operates the Gemini Digital Twins Platform, an in silico causal AI system that builds computational models of human disease biology from patient multiomics and clinical datasets. The platform is used in collaboration with biopharma partners to identify novel molecular intervention points and accelerate drug discovery and development across oncology, neurodegenerative, immunological, and cardiometabolic diseases.
Product overview
Aitia offers a single unified platform called the Gemini Digital Twins, which uses a causal AI reverse-engineering forward-simulation (REFS) engine combined with supercomputing power and massive patient multiomics and clinical datasets. This platform creates in silico models of human disease biology that drive drug discovery and development across the biopharma pipeline, including applications in oncology, neurodegenerative, immunological, and cardiometabolic diseases.
Differentiator
Problem solved
Functional benefit
Brands
- Gemini Digital Twins: A causal AI-based platform for building in silico models of human disease biology using multiomics and clinical datasets to inform drug discovery and development.
Products and services
- Gemini Digital Twins Platform An in silico causal AI platform that builds digital twin models of human disease biology using the proprietary REFS engine, supercomputing power, and massive patient multiomics and clinical datasets. The platform is designed for biopharma partners to discover, develop, and test novel therapeutics across oncology, neurodegenerative, immunological, and cardiometabolic diseases by identifying novel molecular intervention points before expensive laboratory and clinical work.
Quantifiable outcome
- Reveals novel potential intervention points for drug discovery through causal understanding of molecular interactions causing diseases
Companies that use Aitia
Customer profileSegments5 records
Ideal customer profiles1 record
Aitia technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability3 records
Feature3 records
Aitia partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Gustave RoussycoreAitia and Gustave Roussy have joined forces to identify the fundamental biological causes of multiple human cancers. This partnership leverages Gustave Roussy's expertise in oncology research and patient data with Aitia's causal AI and Gemini Digital Twins platform to advance cancer research and drug discovery.
Scale indicators1 record
Recent moves5 records
Expansion highlights4 records
Aitia competitors and assessment
Company assessmentDirect peers
- Recursion Pharmaceuticals: AI-driven drug discovery platform using high-throughput biology and machine learning to identify novel therapeutic candidates. Directly comparable to Aitia in applying AI/ML at scale to biopharma R&D, with overlapping target customers (pharma partners) and similar partnership-based business model.
- Insitro: Machine learning-driven drug discovery and development company combining high-throughput biology with ML models. Comparable to Aitia in using AI/ML for causal or predictive biological insight and in partnering with pharma on discovery programs.
- Exscientia: AI-driven precision medicine company using its own AI platform to design and develop drug candidates, with major pharma partnerships (e.g., Sanofi, Bristol-Myers Squibb). Closely comparable in partnership-driven AI drug discovery model.
- Isomorphic Labs: Alphabet-backed drug discovery company leveraging DeepMind's AI breakthroughs (notably AlphaFold) for computational drug design. Direct competitor applying cutting-edge AI to pharmaceutical R&D with strong pharma partnerships.
- Schrödinger: Physics-based computational platform for drug discovery and materials science with both software and internal drug programs. Comparable in providing computational/simulation-based drug discovery tools and serving biopharma customers.
- BenevolentAI: AI drug discovery company applying machine learning to biomedical knowledge graphs for target identification. Comparable as a European-headquartered AI-driven pharma partner with a similar partnership-plus-pipeline model.
- Atomwise: AI-driven small molecule drug design company using structure-based deep learning models. Comparable in applying AI to identify novel drug candidates and structure partnership deals with pharmaceutical companies.
Emerging players
- XtalPi: AI and quantum physics-driven drug R&D company combining computational prediction with wet-lab validation. Comparable in its AI-plus-computation approach to pharma R&D, with significant Asia presence and growing global partnerships.
- Owkin: AI biotech using federated learning on patient multiomics and clinical data to develop therapeutics and diagnostics. Comparable in leveraging large-scale multiomics/clinical datasets for drug discovery, with pharma partnership revenue model.
- GNS Healthcare: Causal AI and simulation platform applied to oncology and other complex diseases, using patient data to model disease biology and drug response. Comparable in explicitly using causal AI for disease modeling and biopharma R&D applications.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
Aitia social profiles
Digital presenceAitia financial estimates
Financial estimateRevenue estimate
Valuation estimate
Aitia leadership team
Management profileNumber of profiles
Profiles5 records
Aitia funding detail
Funding detailFunding overview
Funding rounds10 records
Investors11 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Aitia M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Aitia
What does Aitia do?
Aitia develops and operates the Gemini Digital Twins Platform, an in silico causal AI system that builds computational models of human disease biology from patient multiomics and clinical datasets. The platform is used in collaboration with biopharma partners to identify novel molecular intervention points and accelerate drug discovery and development across oncology, neurodegenerative, immunological, and cardiometabolic diseases.
Is Aitia a public or private company?
Aitia is a private company. It is classified as venture growth investor backed and is currently operating.
When was Aitia founded?
Aitia was founded in 2000. It employs 11 to 50 people.
Where is Aitia based?
Aitia is headquartered in Somerville, United States, in the North America region.
How does Aitia make money?
One revenue line is on record: pharmaceutical Partnership Programs.
Who are Aitia's main competitors?
Direct peers on record are Recursion Pharmaceuticals, Insitro, Exscientia, Isomorphic Labs, Schrödinger, BenevolentAI and Atomwise. Emerging players are XtalPi, Owkin and GNS Healthcare.
Does Aitia have an API?
No public API is recorded for Aitia.
What industry is Aitia in?
Aitia's product category is Drug Discovery Software. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening). Its NAICS code is 541714 and its SIC code is 7373.